There's a lot of choice on the S&P/ASX 200 index (ASX: XJO), so to narrow things down let's look at a few ASX 200 shares that analysts have named as buys, courtesy of The Bull.
Here's what they are bullish on:
Image source: Getty Images
Northern Star Resources Ltd (ASX: NST)
The team at Shaw and Partners thinks Northern Star could be an ASX 200 share to buy.
The broker highlights the quality of the gold miner's portfolio and proven track record as reasons to buy. It said:
Northern Star remains one of Australia's leading gold producers, offering investors exposure to a supportive gold price environment. The company operates a portfolio of high quality assets with a proven track record of operational delivery and disciplined capital management.
Recent production results have been solid, and ongoing investment in key projects should support future output growth. With global economic uncertainty continuing to support demand for gold, Northern Star is well positioned to generate attractive shareholder returns.
Telix Pharmaceuticals Ltd (ASX: TLX)
Another ASX 200 share that Shaw and Partners is positive on is radiopharmaceutical company Telix.
It likes the company due to its promising pipeline and expanding commercialisation opportunities in key global markets. The broker explains:
Telix continues to benefit from strong demand for its radiopharmaceutical products, particularly in prostate cancer imaging. The company has demonstrated impressive revenue growth and is advancing a promising pipeline across diagnostics and therapeutics.
Recent updates highlight expanding commercialisation opportunities in key global markets, providing multiple avenues for future earnings growth. While the stock can be volatile, its strong industry position and exposure to a rapidly growing health care segment support a positive long term outlook.
Treasury Wine Estates Ltd (ASX: TWE)
Over at MPC Markets, its analysts are bullish on wine giant Treasury Wine and have named it as an ASX 200 share to buy this week.
After a difficult period, MPC Markets appears to believe a change could be coming. It said:
This global wine company reported a statutory net loss after tax of $1.1 billion in full year 2026, driven by a non-cash impairment of US assets. However, the company is transforming how it operates and is forecasting a brighter outlook. Leverage was reduced in the first quarter of 2027, driven by stronger operating cash flow.
In China, the Penfolds brand grew depletions marginally ahead of plan, which was partially driven by increasing consumer demand. The company announced it was on track to realise $100 million a year in cost reductions by fiscal year 2029. The turnaround isn't a done deal, but we like the mix of disciplined asset sales, cost cutting and firming luxury demand. The shares have been enjoying favourable momentum since March.
